Table 1 Baseline Characteristics among Patients Receiving First-Line Multikinase Inhibitor Treatment
Sunitinib | Sorafenib | |
|---|---|---|
(N = 85) | (N = 60) | |
Initial Dose, N (%) | 50 mg QD 85 (100.0) | 400 mg BID 59 (98.3) 400 mg QD 1 (1.7) |
Age at initiation, years | ||
Median (range) | 62.4 (35.1-81.9) | 66.0 (37.9-77.7) |
Mean (std.) | 60.1 (10.4) | 63.2 (9.7) |
Male, N (%) | 74 (87.1) | 53 (88.3) |
ECOG Performance Status, N (%) | ||
0 | 69 (81.2) | 35 (58.3) |
1 | 14 (16.5) | 13 (21.7) |
2 | 0 (0.0) | 1 (1.7) |
NA | 2 (2.4) | 11 (18.3) |
Number of metastatic sites | ||
1 | 8 (9.4) | 9 (15.0) |
2 | 30 (35.3) | 9 (15.0) |
3 | 25 (29.4) | 21 (35.0) |
>3 | 22 (25.9) | 21 (35.0) |
Metastatic sites, N (%) | ||
Bone | 29 (34.1) | 18 (30.0) |
Brain | 14 (16.5) | 10 (16.7) |
Liver | 18 (21.2) | 23 (38.3) |
Lung | 59 (69.4) | 46 (76.7) |
Lymph nodes | 52 (61.2) | 36 (60.0) |
Previous therapy, N (%) | ||
Radiotherapy | 30 (35.3) | 21 (35.0) |
Nephrectomy | 84 (98.8) | 58 (96.7) |
Immunotherapy | 68 (80.0) | 49 (81.7) |
Chemotherapy | 39 (45.9) | 28 (46.7) |